Sanofi-Aventis and Bristol-Myers Squibb’s blockbuster anti-clotting drug Plavix will now carry a boxed warning about the drug’s ineffectiveness in some patients with a genetic mutation. The warning also advises healthcare professionals that genetic tests are available to identify patients whose bodies can’t metabolize Plavix (clopidogrel bisulfate) well, and other anti-platelet medications should be used for those patients, the FDA says.
Washington Drug Letter